Johnson & Johnson (NYSE:JNJ) VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Johnson & Johnson (JNJ) traded up 0.67% on Wednesday, hitting $134.27. The stock had a trading volume of 2,399,705 shares. The company’s 50 day moving average price is $132.93 and its 200 day moving average price is $126.81. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The firm has a market cap of $360.38 billion, a price-to-earnings ratio of 22.72 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.74 EPS. Analysts expect that Johnson & Johnson will post $7.18 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.
Several hedge funds have recently made changes to their positions in JNJ. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter worth $3,220,322,000. State Street Corp raised its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares during the period. Asset Management One Co. Ltd. raised its stake in Johnson & Johnson by 1,147.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 4,946,229 shares of the company’s stock worth $569,967,000 after buying an additional 4,549,711 shares during the period. BlackRock Inc. raised its stake in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after buying an additional 4,332,612 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after buying an additional 3,289,763 shares during the period. Hedge funds and other institutional investors own 66.10% of the company’s stock.
A number of equities research analysts recently issued reports on JNJ shares. J P Morgan Chase & Co upgraded Johnson & Johnson from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $123.64 to $140.00 in a research report on Monday, May 15th. UBS AG reiterated a “buy” rating and issued a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Vetr downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 price objective on the stock. in a research report on Monday, May 15th. Finally, BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a research report on Wednesday, April 19th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $134.12.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.